Frontiers in Oncology (Jul 2020)
Optimizing MR-Guided Radiotherapy for Breast Cancer Patients
- Maureen L. Groot Koerkamp,
- Jeanine E. Vasmel,
- Nicola S. Russell,
- Simona F. Shaitelman,
- Carmel N. Anandadas,
- Adam Currey,
- Danny Vesprini,
- Brian M. Keller,
- Chiara De-Colle,
- Kathy Han,
- Lior Z. Braunstein,
- Faisal Mahmood,
- Faisal Mahmood,
- Ebbe L. Lorenzen,
- Marielle E. P. Philippens,
- Helena M. Verkooijen,
- Jan J. W. Lagendijk,
- Antonetta C. Houweling,
- H. J. G. Desiree van den Bongard,
- Anna M. Kirby
Affiliations
- Maureen L. Groot Koerkamp
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- Jeanine E. Vasmel
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- Nicola S. Russell
- Department of Radiotherapy, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- Simona F. Shaitelman
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
- Carmel N. Anandadas
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom
- Adam Currey
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
- Danny Vesprini
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Brian M. Keller
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Chiara De-Colle
- Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany
- Kathy Han
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
- Lior Z. Braunstein
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Faisal Mahmood
- 0Department of Oncology, Odense University Hospital, Odense, Denmark
- Faisal Mahmood
- 1Research Unit for Oncology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- Ebbe L. Lorenzen
- 0Department of Oncology, Odense University Hospital, Odense, Denmark
- Marielle E. P. Philippens
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- Helena M. Verkooijen
- 2Imaging Division, University Medical Center Utrecht, Utrecht, Netherlands
- Jan J. W. Lagendijk
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- Antonetta C. Houweling
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- H. J. G. Desiree van den Bongard
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
- Anna M. Kirby
- 3Department of Radiotherapy, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom
- DOI
- https://doi.org/10.3389/fonc.2020.01107
- Journal volume & issue
-
Vol. 10
Abstract
Current research in radiotherapy (RT) for breast cancer is evaluating neoadjuvant as opposed to adjuvant partial breast irradiation (PBI) with the aim of reducing the volume of breast tissue irradiated and therefore the risk of late treatment-related toxicity. The development of magnetic resonance (MR)–guided RT, including dedicated MR-guided RT systems [hybrid machines combining an MR scanner with a linear accelerator (MR-linac) or 60Co sources], could potentially reduce the irradiated volume even further by improving tumour visibility before and during each RT treatment. In this position paper, we discuss MR guidance in relation to each step of the breast RT planning and treatment pathway, focusing on the application of MR-guided RT to neoadjuvant PBI.
Keywords
- breast cancer
- neoadjuvant radiation therapy
- partial breast irradiation
- MR-guided radiotherapy
- hybrid machine
- MR-linac
